year,risk_factors
2021,"Risks Related to Our Business, Industry and Operations, and Business Development:
Risks Related to Government Regulation and Legal Proceedings
Risks Related to Intellectual Property, Technology and Security:
Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)
Eliquis 
Xtandi 
•
Bavencio 
Orgovyx 
WRDM. 
GPD. 
Science-based platform-services organizations.
.
Drug and Biologic Regulation
. 
Biosimilar Regulation.
Sales and Marketing Regulations
.
Healthcare Reform
.
Pricing and Reimbursement
.
Anti-Corruption. 
Data Privacy. 
New Drug Approvals.
Pharmacovigilance.
 
Pricing and Reimbursement
. 
Healthcare Provider Transparency and Disclosures.
Intellectual Property
.
Data Privacy. 
Diversity, Equity and Inclusion.
Colleague Engagement
Performance, Leadership and Growth.
Health, Safety and Well-Being.
Pay Equity.
MANAGED CARE TRENDS
COMPETITIVE PRODUCTS
CONCENTRATION
RESEARCH AND DEVELOPMENT 
GLOBAL OPERATIONS
PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES 
COUNTERFEIT PRODUCTS
PRICING AND REIMBURSEMENT
U.S. HEALTHCARE REFORM
DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
POST-APPROVAL DATA
LEGAL MATTERS
INTELLECTUAL PROPERTY PROTECTION
THIRD PARTY INTELLECTUAL PROPERTY CLAIMS
INFORMATION TECHNOLOGY AND SECURITY 
BUSINESS DEVELOPMENT ACTIVITIES
SPIN-OFF AND COMBINATION OF UPJOHN WITH MYLAN
CONSUMER HEALTHCARE JV WITH GSK
COVID-19 PANDEMIC
MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS
COST AND EXPENSE CONTROL AND NONORDINARY EVENTS
INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
CHANGES IN LAWS AND ACCOUNTING STANDARDS
Acquisitions and Fair Value
Revenues
Asset Impairments
Identifiable Intangible Assets
Goodwill
Benefit Plans
Expected Annual Rate of Return on Plan Assets
Discount Rate Used to Measure Plan Obligations
Anticipated Change in Accounting Policy
Income Tax Assets and Liabilities
Contingencies
Revenue Deductions
Transforming to a More Focused Company Program
Purchase Accounting Adjustments
Acquisition-Related Costs
Discontinued Operations
Certain Significant Items
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items
Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income
Cash Flows from Continuing Operations
Cash Flows from Discontinued Operations
Debt Capacity—Lines of Credit
Selected Measures of Liquidity and Capital Resources
Credit Ratings
LIBOR
Gl
bal Economic Conditions
Market Risk
Contractual Obligations
Off-Balance Sheet Arrangements
Share-Purchase Plans and Accelerated Share Repurchase Agreements
Dividends on Common Stock
Recently Adopted Accounting Standards
A. Basis of Presentation
B
New Accounting Standards Adopted in 2020
C. Estimates and Assumptions
D. Acquisitions
E. Fair Value
F. Foreign Currency Translation
G
Revenues and Trade Accounts Receivable
H. Collaborative Arrangements
I. Cost of Sales and Inventories
J. Selling, Informational and Administrative Expenses
K. Research and Development Expenses
L. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets
M.
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
N. Cash Equivalents and Statement of Cash Flows
O. Investments and Derivative Financial Instruments
P
Tax Assets and Liabilities and Income Tax Contingencies
Q. Pension and Postretirement Benefit Plans
R. Legal and Environmental Contingencies
S. Share-Based Payments
B
Divestitures
C. Equity-Method Investments
D. Licensing Arrangements
E. Collaborative Arrangements
Transforming to a More Focused Company Program
Key Activities
A. Taxes on Income from Continuing Operations
B. Tax Rate Reconciliation
C. Deferred Taxes
D. Tax Contingencies
E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
A. Fair Value Measurements
B. Investments
C. Short-Term Borrowings
D. Long-Term Debt
E. Derivative Financial Instruments and Hedging Activities
F
 Credit Risk
A. Identifiable Intangible Assets
Developed Technology Rights
Brands
IPR&D
Licensing Agreements
Amortization
B. Goodwill
A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)
B. Actuarial Assumptions
C. Obligations and Funded Status
D. Plan Assets
E. Cash Flows
F. Defined Contribution Plans
A. Common Stock Purchases
B. Preferred Stock and Employee Stock Ownership Plans
A. Legal Proceedings
A1. Legal Proceedings––Patent Litigation
A2. Legal Proceedings––Product Litigation
A3. Legal Proceedings––Commercial and Other Matters
A4. Legal Proceedings––Government Investigations
A5. Legal Proceedings––Matters Resolved During 2020
B. Guarantees and Indemnifications
C. Certain Commitments
D. Contingent Consideration for Acquisitions
E. Insurance
A. Geographic Information
B. Other Revenue Information"
2022,"Risks Related to Our Business, Industry and Operations, and Business Development:
Risks Related to Government Regulation and Legal Proceedings
Risks Related to Intellectual Property, Technology and Security:
Comirnaty/BNT162b2
Eliquis 
Xtandi 
•
Bavencio 
•
Orgovyx 
 Myfembree
WRDM. 
GPD. 
 
Science-based platform-services organizations within WRDM.
.
Drug and Biologic Regulation
. 
Biosimilar Regulation.
Sales and Marketing Regulations
.
Pricing, Reimbursement and Access Regulations.
Anti-Corruption. 
Data Privacy. 
New Drug Approvals.
Pharmacovigilance.
 
Pricing and Reimbursement
. 
Healthcare Provider Transparency and Disclosures.
Intellectual Property
.
Data Privacy. 
Core Values.
Diversity, Equity and Inclusion.
Colleague Engagement
Performance, Leadership and Growth.
Health, Safety and Well-Being
Pay Equity.
MANAGED CARE TRENDS
COMPETITIVE PRODUCTS
CONCENTRATION
RESEARCH AND DEVELOPMENT 
GLOBAL OPERATIONS
PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES 
COUNTERFEIT PRODUCTS
PRICING AND REIMBURSEMENT
U.S. HEALTHCARE REGULATION
DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
POST-AUTHORIZATION/APPROVAL DATA
LEGAL MATTERS
INTELLECTUAL PROPERTY PROTECTION
THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS
INFORMATION TECHNOLOGY AND SECURITY 
BUSINESS DEVELOPMENT ACTIVITIES
SPIN-OFF AND COMBINATION OF UPJOHN WITH MYLAN
CONSUMER HEALTHCARE JV WITH GSK
COVID-19 PANDEMIC
MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS
COST AND EXPENSE CONTROL AND NONORDINARY EVENTS
INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
CHANGES IN LAWS AND ACCOUNTING STANDARDS
Acquisitions
Revenues
Asset Impairments
Identifiable Intangible Assets
Goodwill
Benefit Plans
Expected Annual Rate of Return on Plan Assets
Discount Rate Used to Measure Plan Obligations
Income Tax Assets and Liabilities
Contingencies
Revenue Deductions
Cost of Sales
Selling, Informational and Administrative (SI&A) Expenses
Research and Development (R&D) Expenses
Amortization of Intangible Assets
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
Transforming to a More Focused Company Program
Other (Income)/Deductions––Net
Provision/(Benefit) for Taxes on Income
Discontinued Operations
Purchase Accounting Adjustments
Acquisition-Related Items
Discontinued Operations
Certain Significant Items
Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items
Cash Flows from Continuing Operations
Cash Flows from Discontinued Operations
Credit Ratings
Capital Allocation Framework
Off-Balance Sheet Arrangements, Contractual, and Other Obligations
Gl
bal Economic Conditions
Market Risk
LIBOR
Recently Adopted Accounting Standard
A. Basis of Presentation
B
New Accounting Standard Adopted in 2021
D. Estimates and Assumptions
E. Acquisitions
F. Fair Value
G. Foreign Currency Translation
H. Revenues and Trade Accounts Receivable
I. Collaborative Arrangements
J. Cost of Sales and Inventories
K. Selling, Informational and Administrative Expenses
L. Research and Development Expenses
M. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets
N. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
O. Cash Equivalents and Statement of Cash Flows
P. Investments and Derivative Financial Instruments
Q. Tax Assets and Liabilities and Income Tax Contingencies
R. Pension and Postretirement Benefit Plans
S. Legal and Environmental Contingencies
T. Share-Based Payments
B. Divestitures
C. Equity-Method Investments
D. Licensing Arrangements
E. Collaborative Arrangements
A. Transforming to a More Focused Company Program
B. Key Activities
A. Taxes on Income from Continuing Operations
B. Tax Rate Reconciliation
C. Deferred Taxes
D. Tax Contingencies
E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
A. Fair Value Measurements
B. Investments
C. Short-Term Borrowings
D. Long-Term Debt
E. Derivative Financial Instruments and Hedging Activities
F
 Credit Risk
A. Identifiable Intangible Assets
Developed Technology Rights
Brands
IPR&D
Licensing Agreements
Amortization
B. Goodwill
A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)
B. Actuarial Assumptions
C. Obligations and Funded Status
D. Plan Assets
E. Cash Flows
F. Defined Contribution Plans
A. Common Stock Purchases
B. Preferred Stock and Employee Stock Ownership Plans
A. Legal Proceedings
A1. Legal Proceedings––Patent Litigation
A2. Legal Proceedings––Product Litigation
A3. Legal Proceedings––Commercial and Other Matters
A4. Legal Proceedings––Government Investigations
A5. Legal Proceedings––Matters Resolved During 2021
B. Guarantees and Indemnifications
C. Certain Commitments
D. Contingent Consideration for Acquisitions
E. Insurance
A. Segment Information
B. Geographic Information
C. Other Revenue Information"
2023,"Risks Related to Our Business, Industry and Operations, and Business Development:
Risks Related to Government Regulation and Legal Proceedings
Risks Related to Intellectual Property, Technology and Security:
WRDM. 
GPD. 
 
Comirnaty
Eliquis 
Xtandi 
•
Bavencio 
•
Orgovyx 
 Myfembree
.
Drug and Biologic Regulation
. 
Biosimilar Regulation.
Sales and Marketing Regulations
.
Pricing, Reimbursement and Access Regulations.
Anti-Corruption. 
Data Privacy. 
New Drug Approvals
Pharmacovigilance.
 
Pricing and Reimbursement
. 
Healthcare Provider Transparency and Disclosures.
Intellectual Property
.
Data Privacy. 
Core Values.
Diversity, Equity and Inclusion.
Colleague Engagement
Performance, Leadership and Growth.
Health, Safety and Well-Being
Pay Equity.
MANAGED CARE TRENDS
COMPETITIVE PRODUCTS
CONCENTRATION
RESEARCH AND DEVELOPMENT 
GLOBAL OPERATIONS
PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES 
COUNTERFEIT PRODUCTS
PRICING AND REIMBURSEMENT
U.S. HEALTHCARE REGULATION
DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
POST-AUTHORIZATION/APPROVAL DATA
LEGAL MATTERS
INTELLECTUAL PROPERTY PROTECTION
THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS
INFORMATION TECHNOLOGY AND SECURITY 
BUSINESS DEVELOPMENT ACTIVITIES
COVID-19
CLIMATE CHANGE AND SUSTAINABILITY
MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS
COST AND EXPENSE CONTROL AND NONORDINARY EVENTS
INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
CHANGES IN LAWS AND ACCOUNTING STANDARDS
Acquisitions
Revenues
Asset Impairments
Identifiable Intangible Assets
Goodwill
Benefit Plans
Expected Annual Rate of Return on Plan Assets
Discount Rate Used to Measure Plan Obligations
Income Tax Assets and Liabilities
Contingencies
Cost of Sales
Selling, Informational and Administrative Expenses
Research and Development Expenses
Acquired In-Process Research and Development Expenses
Amortization of Intangible Assets
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
Transforming to a More Focused Company Program
Other (Income)/Deductions––Net
Adjusted Income and Adjusted Diluted EPS
Amortization of Intangible Assets
Acquisition-Related Items
Discontinued Operations
Certain Significant Items
Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items
Cash Flows from Continuing Operations
Cash Flows from Discontinued Operations
Credit Ratings
Capital Allocation Framework
Off-Balance Sheet Arrangements, Contractual, and Other Obligations
Global Economic Conditions
Market Risk
LIBOR
Recently Adopted Accounting Standard
A. Basis of Presentation
B
New Accounting Standard Adopted in 2022
C. Estimates and Assumptions
D. Acquisitions
E. Fair Value
F. Foreign Currency Translation
G. Revenues and Trade Accounts Receivable
H. Collaborative Arrangements
I. Cost of Sales and Inventories
J. Selling, Informational and Administrative Expenses
K. Research and Development Expenses
L. Acquired In-Process Research and Development Expenses
M. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets
N. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
O. Cash Equivalents and Statement of Cash Flows
P. Investments and Derivative Financial Instruments
Q. Tax Assets and Liabilities and Income Tax Contingencies
R. Pension and Postretirement Benefit Plans
S. Legal and Environmental Contingencies
T. Share-Based Payments
B. Divestitures
C. Equity-Method Investments
D. Licensing Arrangements
E. Collaborative Arrangements
A. Transforming to a More Focused Company Program
B. Key Activities
A. Taxes on Income from Continuing Operations
B. Tax Rate Reconciliation
C. Deferred Taxes
D. Tax Contingencies
E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
A. Fair Value Measurements
B. Investments
C. Short-Term Borrowings
D. Long-Term Debt
E. Derivative Financial Instruments and Hedging Activities
F. Credit Risk
A. Identifiable Intangible Assets
B. Goodwill
A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)
B. Actuarial Assumptions
C. Obligations and Funded Status
D. Plan Assets
E. Cash Flows
F. Defined Contribution Plans
A. Common Stock Purchases
B. Preferred Stock and Employee Stock Ownership Plans
A. Legal Proceedings
A1. Legal Proceedings––Patent Litigation
A2. Legal Proceedings––Product Litigation
A3. Legal Proceedings––Commercial and Other Matters
A4. Legal Proceedings––Government Investigations
B. Guarantees and Indemnifications
C. Certain Commitments
D. Contingent Consideration for Acquisitions
E. Insurance
A. Segment Information
B. Geographic Information
C. Other Revenue Information"
2024,"Risks Related to Our Business, Industry and Operations, and Business Development:
Risks Related to Government Regulation and Legal Proceedings
Risks Related to Intellectual Property, Technology and Security:
Comirnaty
Eliquis 
Xtandi 
Orgovyx 
 Myfembree
Padcev 
.
Drug and Biologic Regulation
. 
Biosimilar Regulation.
Sales and Marketing Regulations
.
Pricing, Reimbursement and Access Regulations.
Anti-Corruption. 
Data Privacy. 
New Drug Approvals
Pharmacovigilance.
 
Pricing and Reimbursement
. 
Healthcare Provider Transparency and Disclosures.
Intellectual Property
.
Data Privacy. 
Core Values.
Diversity, Equity and Inclusion.
Colleague Engagement
Performance and Leadership.
Growth and Development
Health, Safety and Well-Being
Pay Equity.
MANAGED CARE TRENDS
COMPETITIVE PRODUCTS
CONCENTRATION
RESEARCH AND DEVELOPMENT 
GLOBAL OPERATIONS
PRODUCT MANUFACTURING, SALES AND MARKETING RISKS
COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES 
COUNTERFEIT PRODUCTS
PRICING AND REIMBURSEMENT
U.S. HEALTHCARE REGULATION
DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS
POST-AUTHORIZATION/APPROVAL DATA
LEGAL MATTERS
INTELLECTUAL PROPERTY PROTECTION
THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS
INFORMATION TECHNOLOGY AND SECURITY 
BUSINESS DEVELOPMENT ACTIVITIES AND STRATEGIC GOALS
PANDEMICS
COVID-19
CLIMATE CHANGE AND SUSTAINABILITY
MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS
COST AND EXPENSE CONTROL AND NONORDINARY EVENTS
INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS
CHANGES IN LAWS AND ACCOUNTING STANDARDS
Acquisitions
Revenues
Asset Impairments
Identifiable Intangible Assets
Goodwill
Benefit Plans
Expected Annual Rate of Return on Plan Assets
Discount Rate Used to Measure Plan Obligations
Income Tax Assets and Liabilities
Contingencies
Cost of Sales
Selling, Informational and Administrative Expenses
Research and Development Expenses
Acquired In-Process Research and Development Expenses
Amortization of Intangible Assets
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
Transforming to a More Focused Company Program
Realigning our Cost Base Program
Other (Income)/Deductions––Net
Upjohn Separation Costs
Adjusted Income and Adjusted Diluted EPS
Amortization of Intangible Assets
Acquisition-Related Items
Discontinued Operations
Certain Significant Items
Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items
Cash Flows from Continuing Operations
Financing for Seagen Acquisition
Credit Ratings
Capital Allocation Framework
Off-Balance Sheet Arrangements, Contractual, and Other Obligations
Global Economic Conditions
Market Risk
Recently Adopted Accounting Standards
A. Basis of Presentation
B
New Accounting Standards Adopted in 2023
C. Estimates and Assumptions
D. Acquisitions
E. Fair Value
F. Foreign Currency Translation
G. Revenues and Trade Accounts Receivable
H. Collaborative Arrangements
I. Cost of Sales and Inventories
J. Selling, Informational and Administrative Expenses
K. Research and Development Expenses
L. Acquired In-Process Research and Development Expenses
M. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets
N. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
O. Cash Equivalents and Statement of Cash Flows
P. Investments and Derivative Financial Instruments
Q. Tax Assets and Liabilities and Income Tax Contingencies
R. Pension and Postretirement Benefit Plans
S. Legal and Environmental Contingencies
T. Share-Based Payments
B. Divestitures
C. Equity-Method Investments
D. Licensing Arrangement
E. Collaborative Arrangements
F. Research and Development Arrangement
A. Restructuring Programs
B. Key Activities
A. Taxes on Income from Continuing Operations
B. Tax Rate Reconciliation
C. Deferred Taxes
D. Tax Contingencies
E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
A. Fair Value Measurements
B. Investments
C. Short-Term Borrowings
D. Long-Term Debt
E. Derivative Financial Instruments and Hedging Activities
F. Credit Risk
A. Identifiable Intangible Assets
B. Goodwill
A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)
B. Actuarial Assumptions
C. Obligations and Funded Status
D. Plan Assets
E. Cash Flows
F. Defined Contribution Plans
A. Common Stock Purchases
B. Employee Stock Ownership Plans
A. Legal Proceedings
A1. Legal Proceedings––Patent Litigation
A2. Legal Proceedings––Product Litigation
A3. Legal Proceedings––Commercial and Other Matters
A4. Legal Proceedings––Government Investigations
B. Guarantees and Indemnifications
C. Certain Commitments
D. Contingent Consideration for Acquisitions
E. Insurance
A. Segment Information
B. Geographic Information
C. Other Revenue Information"
